ANAB Quote, Financials, Valuation and Earnings

Nektar Therapeutics has a net margin of 19.8% compared to AnaptysBio, Inc.'s net margin of -301.29%. AnaptysBio, Inc.'s return on equity of -367.62% beat Nektar Therapeutics's return on equity of -327.67%.

AnaptysBio, Inc. has a consensus price target of $67.92, signalling upside risk potential of 23.87%. On the other hand Nektar Therapeutics has an analysts' consensus of $123.43 which suggests that it could grow by 68.66%. Given that Nektar Therapeutics has higher upside potential than AnaptysBio, Inc., analysts believe Nektar Therapeutics is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.354, which suggesting that the stock is 64.645% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $76.3M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. AnaptysBio, Inc.'s net income of $15.1M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 9.62x versus 75.46x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of 19.8% compared to AnaptysBio, Inc.'s net margin of 40.17%. AnaptysBio, Inc.'s return on equity of -367.62% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

AnaptysBio, Inc. has a consensus price target of $67.92, signalling upside risk potential of 23.87%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 44.46%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.354, which suggesting that the stock is 64.645% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.137%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $76.3M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. AnaptysBio, Inc.'s net income of $15.1M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 9.62x versus 2.33x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 19.8% compared to AnaptysBio, Inc.'s net margin of -246.76%. AnaptysBio, Inc.'s return on equity of -367.62% beat Vanda Pharmaceuticals, Inc.'s return on equity of -47.32%.

AnaptysBio, Inc. has a consensus price target of $67.92, signalling upside risk potential of 23.87%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 125.95%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.354, which suggesting that the stock is 64.645% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.622, suggesting its less volatile than the S&P 500 by 37.837%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $76.3M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $57.2M. AnaptysBio, Inc.'s net income of $15.1M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$141.2M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 9.62x versus 1.64x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of 19.8% compared to AnaptysBio, Inc.'s net margin of -876.34%. AnaptysBio, Inc.'s return on equity of -367.62% beat Verastem, Inc.'s return on equity of -1773.4%.

AnaptysBio, Inc. has a consensus price target of $67.92, signalling upside risk potential of 23.87%. On the other hand Verastem, Inc. has an analysts' consensus of $16.63 which suggests that it could grow by 191.16%. Given that Verastem, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Verastem, Inc. is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.354, which suggesting that the stock is 64.645% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.56%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $76.3M, which are larger than Verastem, Inc. quarterly revenues of $11.2M. AnaptysBio, Inc.'s net income of $15.1M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 9.62x versus 26.68x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.